05.01.25 -- Navigating CGT Biotech's Financial Headwinds And The Path Forward

Discover why this area is poised to become a leading hub for cell and gene therapy, as highlighted by CCS and industry experts at the 6th Annual Supply Chain Summit.

Ensure seamless access to European clinical trials and markets with GMP-compliant logistics, regulatory support, and risk mitigation to protect the integrity of your advanced therapies.

Monitor assets in real-time, anticipate issues, and maintain optimal performance effortlessly by exploring a cloud-based asset monitoring platform that offers proactive support and rapid response from experts.

Advancing cell and gene therapies for rare pediatric diseases will require innovative trial strategies, early diagnosis, and improved treatment technologies.

Consider several groundbreaking gene editing technologies—TARGATT®, Mad7, and Base Editing—and gain insights into their transformative applications in genetic engineering and therapeutic development.

Explore how to select the right CDMO partner for your pharmaceutical project to navigate the evolving drug development landscape and ensure successful outcomes.

RNA therapeutics hold immense promise for precision treatment, but their development faces challenges. A CDMO with adaptable platforms and flexible timelines can help reduce time and costs.

Producing mRNA therapeutics requires navigating complex manufacturing challenges. A strategic partnership with an integrated CMO streamlines manufacturing processes and reduces costs.

Mathias Kahl, Director of Process Development, shares insights on overcoming challenges in AAV and LV viral vector manufacturing.